Securian Asset Management Inc. Sells 164 Shares of Solventum Co. (NYSE:SOLV)

Securian Asset Management Inc. decreased its holdings in shares of Solventum Co. (NYSE:SOLVFree Report) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,374 shares of the company’s stock after selling 164 shares during the period. Securian Asset Management Inc.’s holdings in Solventum were worth $487,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in SOLV. Modus Advisors LLC acquired a new stake in shares of Solventum in the 4th quarter valued at $25,000. Stonebridge Financial Group LLC acquired a new position in Solventum in the fourth quarter valued at about $26,000. Crews Bank & Trust bought a new stake in Solventum during the fourth quarter worth about $32,000. True Wealth Design LLC increased its holdings in shares of Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after buying an additional 471 shares in the last quarter. Finally, Prospera Private Wealth LLC bought a new position in shares of Solventum in the third quarter valued at approximately $35,000.

Solventum Trading Up 1.2 %

SOLV opened at $75.04 on Tuesday. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The company has a market cap of $12.98 billion and a price-to-earnings ratio of 27.29. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a 50 day simple moving average of $74.65 and a 200 day simple moving average of $71.30.

Analysts Set New Price Targets

A number of research firms recently weighed in on SOLV. Piper Sandler raised their price target on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Wells Fargo & Company lifted their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Bank of America increased their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. The Goldman Sachs Group boosted their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Finally, Mizuho increased their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $79.86.

View Our Latest Report on SOLV

Solventum Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Featured Stories

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLVFree Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.